Boston Scientific price target lowered to $100 from $115 at TD Cowen

TD Cowen analyst Joshua Jennings lowered the firm’s price target on Boston Scientific (BSX) to $100 from $115 and keeps a Buy rating on the shares. The firm views the selloff as an overreaction to results and guidance that were mostly as expected, though with some nits to pick, particularly in EP. Stepping back, despite an H2-weighted outlook which again was anticipated, they are confident the company can post another year of beat-and-raise performances.